Non-estrogen conventional and phytochemical treatments for vasomotor symptoms: what needs to be known for practice

References

• Palacios S, Henderson VW, Siseles N, . Age of menopause and impact of climacteric symptoms by geographical region. Climacteric 2010;13:419–28
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, . Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–77
   PubMed Web of Science ®Google Scholar
• Hunter MS, Grunfeld EA, Mittal S, . Menopausal symptoms in women with breast cancer: prevalence and treatment preferences. Psychooncology 2004;13:769–78
   PubMed Web of Science ®Google Scholar
• Newton KM, Reed SD, LaCroix AZ, . Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med 2006;145:869–79
   PubMed Web of Science ®Google Scholar
• MacLennan A, Broadbent JL, Lester S, . Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;18:CD002978
   Google Scholar
• http://nccam.nih.gov/health/whatiscam/, National Institute of Health. National Center for Complementary and Alternative Medicine
   Google Scholar
• Clayden JR, Bell JW, Pollard P. Menopausal flushing: double blind trial of non-hormonal medication. BMJ 1974;1:409–12
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Loprinzi CL, O'Fallon JR, . Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994;12:155–8
   PubMed Web of Science ®Google Scholar
• Pandya KJ, Raubertas RF, Flynn PJ, . Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000;132:788–93
   PubMed Web of Science ®Google Scholar
• Guttuso TJ Jr. Gabapentin's effects on hot flashes and hypothermia. Neurology 2000;54:2161–3
   PubMed Web of Science ®Google Scholar
• Guttuso T Jr, Kurlan R, McDermott MP, . Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003;101:337–45
   PubMed Web of Science ®Google Scholar
• Pandya KJ, Morrow GR, Roscoe JA, . Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005;366: 818–24
   PubMed Web of Science ®Google Scholar
• Toulis KA, Tzellos T, Kouvelas D, . Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis. Clin Ther 2009;31:221–35
   PubMed Web of Science ®Google Scholar
• Butt DA, Lock M, Lewis JE, . Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. Menopause 2008;15:310–18
   PubMed Web of Science ®Google Scholar
• Dogukan A, Aygen B, Berilgen MS, . Gabapentin-induced coma in a patient with renal failure. Hemodial Int 2006;10: 168–9
   PubMedGoogle Scholar
• Lasso-de-la-Vega MC, Zapater P, Such J, . Gabapentin-associated hepatotoxicity. Am J Gastroenterol 2001;96:3460–2
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Qin R, Balcueva EP, . Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol 2010;28:641–7
   PubMed Web of Science ®Google Scholar
• Stearns V, Ullmer L, López JF, . Hot flushes. Lancet 2002;360:1851–61
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Sloan JA, Perez EA, . Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20: 1578–83
   PubMed Web of Science ®Google Scholar
• Barton DL, LaVasseur BI, Sloan JA, . Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol 2010;28:3278–83
   PubMed Web of Science ®Google Scholar
• Suvanto-Luukkonen E, Koivunen R, Sundström H, . Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause 2005;12:18–26
   PubMed Web of Science ®Google Scholar
• Freeman EW, Guthrie KA, Caan B, . Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled study. JAMA 2011;305:267–74
   PubMed Web of Science ®Google Scholar
• Wu MF, Hilsenbeck SG, Tham YL, . The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer. Breast Cancer Res Treat 2009;118:369–75
   PubMed Web of Science ®Google Scholar
• Kerwin JP, Gordon PR, Senf JH. The variable response of women with menopausal hot flashes when treated with sertraline. Menopause 2007;14:820–2
   PubMedGoogle Scholar
• Grady D, Cohen B, Tice J, . Ineffectiveness of sertraline for treatment of menopausal hot flushes: a randomized controlled trial. Obstet Gynecol 2007;109:823–30
   PubMed Web of Science ®Google Scholar
• Gordon PR, Kerwin JP, Boesen KG, . Setraline to treat hot flashes: a randomized controlled, double-blind, crossover trial in a general population. Menopause 2006;13:546–8
   PubMedGoogle Scholar
• Kimmick GG, Lovato J, McQuellon R, . Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J 2006;12:114–22
   PubMed Web of Science ®Google Scholar
• Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003;289:2827–34
   PubMed Web of Science ®Google Scholar
• Stearns V, Slack R, Greep N, . Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol 2005;23:6919–30
   PubMed Web of Science ®Google Scholar
• van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993;24:203–20
   PubMed Web of Science ®Google Scholar
• Stearns V, Johnson MD, Rae JM, . Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin uptake inhibitor paroxetine. J Natl Cancer Inst 2003;95:1758–64
   PubMed Web of Science ®Google Scholar
• Jin Y, Desta Z, Stearns V, . CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30–9
   PubMed Web of Science ®Google Scholar
• Kelly CM, Juurlink DN, Gomes T, . Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010:340: c693
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Kugler JW, Sloan JA, . Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059–63
   PubMed Web of Science ®Google Scholar
• Evans ML, Pritts E, Vittinghoff E, . Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005;105:161–6
   PubMed Web of Science ®Google Scholar
• Ladd CO, Newport DJ, Ragan KA, . Venlafaxine in the treatment of depressive and vasomotor symptoms in women with perimenopausal depression. Depress Anxiety 2005;22: 94–7
   PubMed Web of Science ®Google Scholar
• Carpenter JS, Storniolo AM, Johns S, . Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer. Oncologist 2007;12:124–35
   PubMed Web of Science ®Google Scholar
• Nichols AI, Tourian KA, Tse SY, . Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor. Expert Opin Drug Metab Toxicol 2010;6:1565–74
   PubMed Web of Science ®Google Scholar
• Speroff L, Gass M, Constantine G, Olivier S, for the Study 315 Investigators. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008;111:77–87
   PubMed Web of Science ®Google Scholar
• Archer D, Dupont CM, Constantine GD, Pickar JH, Olivier S, for the Study 319 Investigators. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety respectively. Am J Obstet Gynecol 2009;200:238.e1–e10
   PubMed Web of Science ®Google Scholar
• Nichols AI, Richards LS, Behrle JA, . The pharmacokinetics and safety of desvenlafaxine in subjects with chronic renal impairment. Int J Clin Pharmacol Therapeutics 2011;49:3–13
   PubMed Web of Science ®Google Scholar
• Joffe H, Soares CN, Petrillo LF, . Treatment of depression and menopause-related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine. J Clin Psychiatry 2007;68: 943–50
   PubMed Web of Science ®Google Scholar
• Cheema D, Coomarasamy A, El-Toukhy T. Non-hormonal therapy of post-menopausal vasomotor symptoms: a structured evidence-based review. Arch Gynecol Obstet 2007;276:463–9
   PubMedGoogle Scholar
• Rada G, Daniel Capurro D, Tomas Pantoja T, . Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Systematic Rev 2010, Issue 9. Art. No.: CD004923
   PubMed Web of Science ®Google Scholar
• US Dietary Supplement Health and Education Act of 1994, Public Law 103–417, 103RD Congress (1994)
   Google Scholar
• Manach C, Hubert J, Llorach R, . The complex links between dietary phytochemicals and human health deciphered by metabolomics. Mol Nutr Food Res 2009;53:1303–15
   PubMed Web of Science ®Google Scholar
• http://www.efsa.europa.eu/
   Google Scholar
• Dietary Supplement Full Implementation and Inforcement Act of 2010, S 3414, 111th Cong, 2nd Sess (2010)
   Google Scholar
• Sakata K, Ohyanagi H, Hiroya Nobori H, . Soybean proteome database: a data resource for plant differential omics. J Proteome Res 2009;8:3539–48
   PubMed Web of Science ®Google Scholar
• Booth NL, Overk CR, Yao P, . The chemical and biological profile of a red clover (Trifolium pratense) phase II clinical extract. J Altern Complement Med 2006;12:133–9
   PubMed Web of Science ®Google Scholar
• Atkinson C, Frankenfeld CL, Lampe JW. Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health. Exp Biol Med 2005;230:155–70
   PubMed Web of Science ®Google Scholar
• Brandon DL, Bates AH, Friedman M. ELISA analysis of soybean trypsin inhibitors in processed foods. Adv Exp Med Biol 1991; 289:321–37
   PubMedGoogle Scholar
• Speroni Aguirre FJ, Milesi V, Añón MC. Effect of extraction and precipitation conditions during soybean protein isolate production on the genistein series content. J Am Oil Chem Soc 2007; 84:305–14
   Web of Science ®Google Scholar
• Kim SH, Jung WS, Ahn JK, . Analysis of isoflavone concentration and composition in soybean [Glycine max (L.)] seeds between the cropping year and storage for 3 years. Eur Food Res Tech 2007;220:207–14
   Web of Science ®Google Scholar
• Booth NL, Overk CR, Yao P, . Seasonal variation of red clover (Trifolium pratense L., Fabaceae) isoflavones and estrogenic activity. J Agric Food Chem 2006;54:1277–82
   PubMed Web of Science ®Google Scholar
• Lampe JW, Chang JL. Interindividual differences in phytochemical metabolism and disposition. Semin Cancer Biol 2007;17: 347–53
   PubMed Web of Science ®Google Scholar
• Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol – a clue to the effectiveness of soy and its isoflavones. J Nutr 2002;132:3577–84
   PubMed Web of Science ®Google Scholar
• Lampe J, Karr S, Hutchins A, . Urinary equol excretion with a soy challenge: influence of habitual diet. Proc Soc Exp Biol Med 1998;217:335–9
   PubMed Web of Science ®Google Scholar
• Tew BY, Xu X, Huei-Ju W, . A diet high in wheat fiber decreases the bioavailability of soybean isoflavones in a single meal fed to women. J Nutr 1996;126:871–7
   PubMed Web of Science ®Google Scholar
• Kuiper GGJM, Lemmen JG, Carlsson B, . Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 1998;139:4252–63
   PubMed Web of Science ®Google Scholar
• Pfitscher A, Reiter E, Jungbauer A. Receptor binding and transactivation activities of red clover isoflavones and their metabolites. J Steroid Biochem Mol Biol 2008;112:87–94
   PubMed Web of Science ®Google Scholar
• Koehler KF, Helguero LA, Haldosén LA, . Reflections on the discovery and significance of estrogen receptor β. Endocr Rev 2005;26:465–78
   PubMed Web of Science ®Google Scholar
• Nilsson S, Gustafsson J-Å. Estrogen receptors: therapies targeted to receptor subtypes. Clin Pharmacol Therap 2011;89:44–55
   PubMed Web of Science ®Google Scholar
• Routledge EJ, White R, Parker MG, . Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor (ER) alpha and ER beta. J Biol Chem 2000;275:35986–93
   PubMed Web of Science ®Google Scholar
• Beck E, Unterrieder E, Krenn L, . Comparison of hormonal activity (estrogen, androgen and progestin) of standardized plant extracts for large scale use in hormone replacement therapy. J Steroid Biochem Mol Biol 2003;84:259–68
   PubMed Web of Science ®Google Scholar
• Dechaud H, Ravard C, Claustrat F, . Xenoestrogen interaction with human sex hormone-binding globulin (hSHBG). Steroids 1999;64:328–34
   PubMed Web of Science ®Google Scholar
• Kennelly EJ, Baggett S, Nuntanakorn P, . Analysis of thirteen populations of black cohosh for formononetin. Phytomedicine 2002;9:461–7
   PubMed Web of Science ®Google Scholar
• Jiang B, Kronenberg F, Balick MJ, . Analysis of formononetin from black cohosh (Actaea racemosa). Phytomedicine 2006;13:477–86
   PubMed Web of Science ®Google Scholar
• Avula B, Wang YH, Smillie TJ, . Quantitative determination of triterpenoids and formononetin in rhizomes of black cohosh (Actaea racemosa) and dietary supplements by using UPLC-UV/ELS detection and identification by UPLC-MS. Planta Med 2009;75:381–6
   PubMed Web of Science ®Google Scholar
• Liske E, Hanggi W, Henneicke-von Zepelin H, . Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. J Womens Health Gend Based Med 2002;11:163–74
   PubMedGoogle Scholar
• Burdette JE, Liu J, Chen S, . Black cohosh acts as a mixed competitive ligand and partial agonist of the serotonin receptor. J Agric Food Chem 2003;51:5661–70
   PubMed Web of Science ®Google Scholar
• Popp M, Schenk R, Abel G. Cultivation of Cimicifuga racemosa (L.) nuttal and quality of CR extract BNO 1055. Maturitas 2003;44:S1–7
   PubMed Web of Science ®Google Scholar
• Lethaby A, Marjoribanks J, Kronenberg F, . Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Systematic Rev 2007, Issue 4. Art. No.: CD001395
   Web of Science ®Google Scholar
• Faure ED, Chantre P, Mares P. Effects of a standardized soy extract on hot flushes: a multicenter, double-blind, randomized, placebo-controlled study. Menopause 2002;9:329–34
   PubMed Web of Science ®Google Scholar
• Bicca ML de O, Horta BL, Lethaby AE. Double-blind randomized clinical trial to assess the effectiveness of soy isoflavones in the relief of climacteric symptoms. Unpublished data, cited in Cochrane Database of Systematic Reviews 2007
   Google Scholar
• Khaodhiar L, Ricciotti HA, Li L, . Daidzein-rich isoflavone aglycones are potentially effective in reducing hot flashes in menopausal women. Menopause 2008;15:125–32
   PubMed Web of Science ®Google Scholar
• Tice JA, Ettinger B, Ensrud K, . Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) study: a randomized controlled trial. JAMA 2003;290:207–14
   PubMed Web of Science ®Google Scholar
• Baber RJ, Templeman C, Morton T, . Randomized placebo-controlled trial of an isoflavone supplement and menopausal symptoms in women. Climacteric 1999;2:85–92
   PubMedGoogle Scholar
• Knight DC, Howes JB, Eden JA. The effect of Promensil, an isoflavone extract, on menopausal symptoms. Climacteric 1999; 2:79–84
   PubMedGoogle Scholar
• van de Weijer PH, Barentsen R. Isoflavones from red clover (Promensil) significantly reduce menopausal hot flush symptoms compared with placebo. Maturitas 2002;42:187–93
   PubMed Web of Science ®Google Scholar
• Hidalgo LA, Chedraui PA, Morocho N, . The effect of red clover isoflavones on menopausal symptoms, lipids and vaginal cytology in menopausal women: a randomized, double blind, placebo-controlled study. Gynecol Endocrinol 2005;21:257–64
   PubMed Web of Science ®Google Scholar
• Li Y, Liu K, Lei W, . Effect of soy isoflavones on peri-menopausal symptom and estrogen. Wei Sheng Yan Jiu 2010;39:56–9
   PubMedGoogle Scholar
• Nahas EA, Nahas-Neto J, Orsatti FL, . Efficacy and safety of a soy isoflavone extract in postmenopausal women: a randomized, double-blind, and placebo-controlled study. Maturitas 2007;58:249–58
   PubMed Web of Science ®Google Scholar
• Carmignani LO, Pedro AO, Costa Paiva LH, . The effect of dietary soy supplementation compared to estrogen and placebo on menopausal symptoms: a randomized controlled trial. Maturitas 2010;67:262–9
   PubMed Web of Science ®Google Scholar
• Chedraui P, San Miguel G, Schwager G. The effect of soy-derived isoflavones over hot flushes, menopausal symptoms and mood in climacteric women with increased body mass index. Gynecol Endocrinol 2011;27:307–13
   PubMed Web of Science ®Google Scholar
• del Giorno C, da Fonseca AM, Bagnoli VR, . Effects of Trifolium pratense on the climacteric and sexual symptoms in postmenopause women. Rev Assoc Med Bras 2010;56:558–62
   PubMed Web of Science ®Google Scholar
• Newton K, Reed S, LaCroix A, . Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med 2006;145:869–79
   PubMed Web of Science ®Google Scholar
• Geller SE, Shulman LP, van Breemen RB, . Safety and efficacy of Black cohosh and Red Clover for the management of vasomotor symptoms: a randomized controlled trial. Menopause 2009;16:1156–66
   PubMed Web of Science ®Google Scholar
• Osmers R, Friede M, Liske E, . Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Obstet Gynecol 2005;105:1074–83
   PubMed Web of Science ®Google Scholar
• Wuttke W, Seidlova-Wuttke D, Gorkow C. The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. Maturitas 2003;44:S67–77
   PubMed Web of Science ®Google Scholar
• Frei-Kleiner S, Schaffner W, Rahlfs V, . Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial. Maturitas 2005;51: 397–404
   PubMed Web of Science ®Google Scholar
• Nappi R, Malavasi B, Brundu B, . Efficacy of Cimicifuga racemosa on climacteric complaints: a randomized study versus low-dose transdermal estradiol. Gynecol Endocrinol 2005; 20:30–5
   PubMed Web of Science ®Google Scholar
• Bai W, Henneicke-von Zepelin H, Wang S, . Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone. Maturitas 2007;58:31–41
   PubMed Web of Science ®Google Scholar
• Uebelhack R, Blohmer JU, Graubaum HJ, . Black cohosh and St. John's wort for climacteric complaints: a randomized trial. Obstet Gynecol 2006;107:247–55
   PubMed Web of Science ®Google Scholar
• Liske E, Hanggi W, Henneicke-von Zepelin H, . Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. J Womens Health Gend Based Med 2002;11:163–74
   PubMedGoogle Scholar
• Pockaj BA, Gallagher JG, Loprinzi CL, . Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. J Clin Oncol 2006;20:2836–41
   Google Scholar
• Verhoeven MO, van der Mooren MJ, van de Weijer PH, . Effect of a combination of isoflavones and Actaea racemosa Linnaeus on climacteric symptoms in healthy symptomatic perimenopausal women: a 12-week randomized, placebo-controlled, double-blind study. Menopause 2005;12:412–20
   PubMed Web of Science ®Google Scholar
• Aso T. Equol improves menopausal symptoms in Japanese women. J Nutr 2010;140:1386S–9S
   PubMed Web of Science ®Google Scholar
• Jou JH, Wu SC, Chang FW, . Effect of intestinal production of equol on menopausal symptoms in women treated with soy isoflavones. Int J Gynaecol Obstet 2008;102:44–9
   PubMed Web of Science ®Google Scholar
• Tempfer CB, Froese G, Heinze G, . Side effects of phytoestrogens: a meta-analysis of randomized trials. Am J Med 2009; 122:939–46
   PubMed Web of Science ®Google Scholar
• Unfer V, Casini ML, Costabile L, . Endometrial effects of long-term treatment with phytoestrogens: a randomized double-blind placebo-controlled study. Fertil Steril 2004; 82:145–8
   PubMed Web of Science ®Google Scholar
• Palacios S, Pornel B, Vásquez F, . Long-term endometrial and breast safety of a specific, standardized soy extract. Climacteric 2010;13:368–75
   PubMed Web of Science ®Google Scholar
• Ju YH. Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. J Nutr 2001;131:2957–62
   PubMed Web of Science ®Google Scholar
• Ju YH, Doerge DR, Alfred CD, . Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res 2002;62:2474–7
   PubMed Web of Science ®Google Scholar
• Ju YH, Doerge DR, Woodling KA, . Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. Carcinogenesis 2008;29:2162–8
   PubMed Web of Science ®Google Scholar
• Ruhlen RL, Haubner J, Tracy JK, . Black cohosh does not exert an estrogenic effect on the breast. Nutr Cancer 2007;59:269–77
   PubMed Web of Science ®Google Scholar
• Davis VL, Jayo MJ, Ho A, . Black cohosh increases metastatic mammary cancer in transgenic mice expressing c-erbB2. Cancer Res 2008;68:8377–83
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Gardner SF, Hubbard MA, . In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4 phenotypes. Clin Pharmacol Ther 2005;77:415–26
   PubMed Web of Science ®Google Scholar
• Rockwell S, Liu Y, Higgins SA. Alteration of the effects of cancer therapy agents on breast cancer cells by the herbal medicine black cohosh. Breast Cancer Res Treat 2005;90:233–9
   PubMed Web of Science ®Google Scholar
• Chow E C-Y, Teo M, Ring JA, . Liver failure associated with the use of black cohosh for menopausal symptoms. MJA 2008;188:420–2
   PubMed Web of Science ®Google Scholar